Cellectar Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Cellectar Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cellectar Biosciences Inc Strategy Report
- Understand Cellectar Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cellectar Biosciences Catalyst Calendar
Proactively evaluate Cellectar Biosciences Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Cellectar Biosciences Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Dec 2019 | Phase I Trial Results | Cellectar Biosciences Inc; National Cancer Institute US | CLRB | iopofosine i-131 | Oncology | Multiple Myeloma (Kahler Disease); Refractory Multiple Myeloma; Relapsed Multiple Myeloma | Company Press Release |
| 01 Dec 2019 | Phase I Trial Initiation | Cellectar Biosciences Inc; National Cancer Institute US; National Institute of Dental and Craniofacial Research; University of Wisconsin Carbone Cancer Center; University of Wisconsin Hospitals and Clinics Authority; University of Wisconsin Madison | CLRB | iopofosine i-131 | Oncology | Head And Neck Cancer; Head And Neck Cancer Squamous Cell Carcinoma | Clinical Trial Registry |
| 28 Sep 2019 | Phase II Trial Results | Cellectar Biosciences Inc; National Cancer Institute US; Syneos Health Inc | CLRB; SYNH | iopofosine i-131 | Hematological Disorders; Oncology | Central Nervous System (CNS) Cancer; Chronic Lymphocytic Leukemia (CLL); CNS Lymphoma; Diffuse Large B-Cell Lymphoma; Hematological Tumor; Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Unspecified B-Cell Lymphomas; Unspecified Hematological Disorders; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer